Filgrastim biosimilar - Apotex/Intas

Drug Profile

Filgrastim biosimilar - Apotex/Intas

Alternative Names: Grastofil; Neukine; Recombinant human granulocyte colony stimulating factor - Intas Biopharmaceuticals; Recombinant human granulocyte colony stimulating factor biosimilar - SciVac Ltd; SciLocyte

Latest Information Update: 10 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intas Biopharmaceuticals
  • Developer Apotex; Intas Biopharmaceuticals; SciVac Ltd
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Haematopoietic cell growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 13 Feb 2015 Preregistration for Neutropenia in USA (IV; SC)
  • 08 Aug 2013 Biomarkers information updated
  • 25 Jul 2013 Preregistration for Neutropenia in European Union (IV; SC) before July 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top